FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Disclosed is an immunoconjugate for the specific induction of T cell cytotoxicity against target cells. The immunoconjugate includes at least one naturally occurring peptide inducing a T cell response. The peptide is capable of being presented through MHC class I connected to an antibody that binds a target cell via a cleavable bond. The peptide inducing a T cell response has at least one cysteine residue and is covalently linked to the antibody via a disulfide bond. Also disclosed are methods for preparing an immunoconjugate and using it to treat a tumour.
EFFECT: effective tumour treatment.
12 cl, 25 dwg, 4 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING PROTEIN AND ITS APPLICATION AS A PRODUCT FOR ADDRESS DELIVERY IN TREATMENT OF CANCER | 2012 |
|
RU2650771C1 |
| NOVEL CELL-PENETRATING PEPTIDES | 2013 |
|
RU2670488C2 |
| HUMANISED ANTIBODIES TO CDCP1 | 2010 |
|
RU2571207C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| PREDICTION OF IMMUNOGENICITY OF T-CELL EPITOPES | 2014 |
|
RU2724370C2 |
| COMPOSITIONS AND METHODS FOR WT1-SPECIFIC IMMUNOTHERAPY | 1999 |
|
RU2237674C2 |
| ANTI-TIM3 ANTIBODIES AND METHODS FOR USING THEM | 2015 |
|
RU2723708C2 |
| COMPOSITION COMPRISING TWO ANTIBODIES ENGINEERED TO HAVE REDUCED AND INCREASED EFFECTOR FUNCTION | 2013 |
|
RU2650788C2 |
| ANTIGEN BINDING PROTEIN AND USE THEREOF AS ADDRESSING PRODUCT FOR TREATMENT OF CANCER | 2012 |
|
RU2659094C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
